Systemic therapy for advanced hepatocellular carcinoma: consideration for selecting second-line treatment
Several molecular-targeted agents have been tested as first- or second-line therapies for hepatocellular carcinoma (HCC) but failed to improve clinical outcomes; sorafenib has been the only approved systemic agent for treating HCC for almost 10 years. Regorafenib resulted in a significant improvemen...
Zapisane w:
| Główni autorzy: | , |
|---|---|
| Format: | Książka |
| Wydane: |
Korean Liver Cancer Association,
2021-09-01T00:00:00Z.
|
| Hasła przedmiotowe: | |
| Dostęp online: | Connect to this object online. |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|
Internet
Connect to this object online.3rd Floor Main Library
| Sygnatura: |
A1234.567 |
|---|---|
| Egzemplarz 1 | Dostępne |